Dec 07 Love0 Non-Incretin Weight Loss: Phase II/III Data on Engineered FGF21 and GDF15 Analogs By Damian Williams Medical Weight Loss Weight-loss care is expanding well beyond the incretin pathway FGF21 and GDF15 analogs are drawing attention because they target metabolism, appetite signaling, and liver fat through different biologic routes. This matters most for…Read More